Fabry Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth ...

At its poster presentation, GC Biopharma unveiled promising non-clinical trial data for its GM1 candidate drug. The results ...

AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...

Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (GLA), which leads to complex multisystemic involvement, with the majority of patients ...

Like we explained, legumes are high in oligosaccharides, so they really have the capacity to trigger some tooting across the ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...

According to research, taking the supplement can help enhance digestion and easy gut problems like bloating, gas and stomach ...

She shared how much healthier she's become after making 'simple' change to her diet by adding one supplement to her daily ...

PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) ...

Oral Platform Presentation: Pompe Disease: Abstract Title: Miglustat: A first-in-class enzyme stabilizer for late-onset Pompe disease Abstract Title: Clinically important improvements in 6-minute walk ...